Impact Plastics and its CEO, Gerald O'Connor, have been sued by the family of one of its Tennessee employees who was killed by catastrophic flooding caused by Hurricane Helene. The wrongful death ...

When it comes to plastic, the rules can be extra confusing -- there's a lot more to it than tossing a water bottle in the recycling bin and calling it a day. Here's why: Not all plastics can be ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Tucked into a green-sounding federal recycling bill ...

As the plastics treaty heads toward the finish line, the debate over limits or caps on virgin resin production has gotten louder, with the Biden administration and now some global businesses ...

"UMass Lowell is among the nation's leading centers for plastics technology, and its Plastics Engineering program...is helping to push new boundaries of how these versatile materials are used, ...

Scientists have new evidence to explain why plastic is dangerous to sea turtles: the animals mistake the scent of plastic for food. Thus, a plastic bag floating in the sea not only looks like a ...

As of 10:52 AM EST. Market Open. VIRGINIA BEACH, VA / ACCESSWIRE / October 22, 2024 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) ("Inspire" or the "Company"), an owner and provider of pet ...

Researchers studying bottlenose dolphins found polyester and other plastics in every animal they tested. By Hiroko Tabuchi Scientists have found plastic pollution almost everywhere they have looked.

Materials such as glass, metal and paper are quite easy to recycle. Certain types of plastic can be recycled too. Objects that aren’t recycled are taken to landfill sites. These are places where ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

Short interest in Inspire Veterinary Partners Inc (NASDAQ:IVP) decreased during the last reporting period, falling from 1.11M to 388.97K. This put 10.86% of the company's publicly available shares ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.